Phase Ib/IIa Study of Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

Trial Profile

Phase Ib/IIa Study of Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Lenalidomide (Primary) ; Romidepsin (Primary)
  • Indications B cell lymphoma; T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Feb 2017 Planned number of patients changed from 30 to 31.
    • 08 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
    • 08 Feb 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top